CSL Awarded EcoVadis Certification

CSL, May 2024

As part of CSL’s sustainability strategy, earlier this year we underwent an assessment with EcoVadis. We are delighted to announce that CSL has received a Silver Medal in our first ever assessment with them.

EcoVadis is an assessment platform that rates businesses’ sustainability based on four key categories: environmental impact, labour & human rights standards, ethics, and procurement practices. Since its formation in 2007, it has conducted over 100,000 assessments for companies across 175 countries, earning a reputation as the gold standard for measuring and certifying sustainability credentials.

Receiving a Silver Medal ranks us among the top 15% of companies evaluated by EcoVadis in the last 12 months, placing us in the 86th percentile. In both Environment and Ethics we are ‘Advanced’ in our sustainability performance. Our EcoVadis Scorecard can be accessed here.

For CSL, this isn’t just about earning a badge.

Sustainability is something that matters at CSL. We see this in our policies, incentives, and green initiatives – see earlier post.

What we are seeing lately, however, is that sustainability is becoming a more significant factor in how organisations appoint suppliers. As an increasing number of companies pledge to lower their emissions and meet sustainability targets, it’s all the more important that they build supply chains that incorporate environmentally and socially responsible practices throughout. This EcoVadis certification allows us to provide transparency and show new and existing customers that we can help them achieve their sustainability goals in their supply chains.

Plus we’ll always deliver very snazzy dashboards, meaningful market insights, and pharma consultancy of course. 😉

This is a great achievement and a solid foundation we can build on in the years to come.

If you’d like to find out more about this certification, you can contact us at info@csl-uk.com or call us on 01483 528302.

Facebook
Twitter
LinkedIn

Featured Article

Economic Factors Squeezing Pharma